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Abstract
OBJECTIVE: To observe the effect of Liandouqing-
mai recipe (Chinese herbal medicine compound
preparation) on the quality of life (QOL) and inflam-
matory reaction of patients with coronary heart dis-
ease (CHD).
METHODS: A total of 101 CHD patients were ran-
domized into two groups: treatment group (n=45)
receiving standard treatment for CHD plus Lian-
douqingmai recipe, and control group (n=56) re-
ceiving standard treatment only. The control group
contained 16 normal healthy subjects. Changes in
hs-C-reactive protein (CRP), peripheral blood leuco-
cytes (PBL), and interleukin (IL)-6 and IL-10 levels
were measured. The Seattle Angina Questionnaire
(SAQ) was used to determine patient QOL before
and after treatment for 2 weeks.
RESULTS: Before treatment, SAQ scores [physical
limitation (PL), angina stability (AS), angina frequen-
cy (AF), treatment satisfaction (TS), and disease per-
ception (DP)] were not statistically different be-
tween groups. After treatment, AS and DP levels of
controls were significantly increased compared
with the other groups, while PL, AS, AF, TS, and DP
levels of the treatment group were significantly in-
creased compared with controls. Treatment group
SAQ scores (PL, AS, AF, TS, and DP) were significant-
ly higher than for controls. CHD patient IL-6 and
IL-10 levels were significantly higher than controls.
Before treatment, mean levels of IL-6, hs-CRP and
PBL of the two groups were not statistically differ-
ent. After treatment, mean levels of IL-6, IL-10,
hs-CRP and PBL of the two groups were significant-
ly decreased compared with their before treatment
values, and levels of IL-6, hs-CRP, and PBL of the
treatment group were lower than controls. Al-
though mean IL-10 levels of both groups de-
creased, there was no significant difference in be-
tween-group and in-group comparisons before
and after treatment. Mean levels of IL-6 and IL-10 in
the normal group were lower than in CHD patients.
SAQ scores of QOL were negatively associated with
the inflammatory index (IL-6/IL-10), and there was a
significant negative association of IL-10 with AS (r=
﹣0.15, P<0.05).
CONCLUSION: Inflammatory reactions in CHD pa-
tients are related to angina status. Coadministra-
tion of CHD standard treatment and Liandouqing-
mai recipe increased patient SAQ scores by decreas-
ing IL-6, IL-10, hs-CRP, and PBL levels in CHD pa-
tients, which might inhibit endothelial inflamma-
tion to improve patient QOL.
© 2014 JTCM. All rights reserved.
539
JTCM |www. journaltcm. com October 15, 2014 |Volume 34 | Issue 5 |
Zhu HJ et al. / Clinical Study
Key words: Coronary disease; C-reactive protein;
Leukocytes; Interleukins; Liandouqingmai recipe;
Seattle angina questionnaires
INTRODUCTION
Coronary heart disease (CHD) is a life-threatening dis-
ease and atherosclerosis (AS) is the pathological basis of
CHD. Our previous studies confirmed that Liandouq-
ingmai recipe, developed by our laboratory, is effective
for the prevention and treatment of AS and CHD. It
decreases the brachial-ankle pulse wave velocity and in-
creases the ankle-brachial index of atherosclerosis pa-
tients when provided as a standard treatment.1 Lian-
douqingmai recipe also decreases low-density lipopro-
tein-cholesterol levels and plasma-induced atherosclero-
sis index of atherosclerosis patients.2 Because it has an-
ti-inflammatory functions that improve arterial rigidity
and decrease levels of high-sensitivity C-reactive pro-
tein (hs-CRP), peripheral blood leucocytes (PBL), in-
terleukin-6 (IL-6) and IL-10, it is commonly used in
clinical practice as a standard treatment.3 This trial was
designed to observe the effect of Liandouqingmai reci-
pe on the quality of life of CHD patients and investi-
gate the correlation between SAQ scores and inflamma-
tory reactions.
METHODS
Patient data
One hundred and one CHD patients and 16 healthy
volunteers took part in this study. The 101 in-patients
of the Heart Internal Medicine Department, Wuxi Tra-
ditional Chinese Medicine (TCM) Hospital, Nanjing
University of Chinese Medicine were enrolled from
June 2007 to December 2009 and were randomized in-
to a Liandouqingmai recipe group (treatment group)
and a standard treatment group (control group) accord-
ing to a random number table. In the treatment group
of 45 patients, there were 20 males and 25 females,
aged 51-87 years [mean age (71±8) years], with a dis-
ease course from 2 h to 28 years [mean (9±11) years].
In the control group of 56 cases, there were 24 males
and 32 females, aged 54-86 years [mean age (70 ± 9)
years], with a disease course from 1 h to 40 years
[mean (9 ± 14) years]. Between the two groups, there
was no statistical difference in age, sex, and disease
course. The 16 healthy volunteers in the normal con-
trol group (normal group) were staff members and
workers at posts or retirees of the study hospital after
age and sex matching. All persons voluntarily taking
part in this research study signed a fact-knowing agree-
ment prior to their inclusion in the study. The study
was approved by the Ethics Committee of Wuxi TCM
Hospital and was performed in accordance with the
ethical standards laid down in the Declaration of Hel-
sinki.
Diagnostic criteria
Diagnostic criteria for CHD followed the naming and
diagnostic criteria of ischemic heart disease issued by
the World Health Organization.4
Inclusion criteria
Patients met the diagnostic criteria of CHD and any
one item of the following conditions: remote myocardi-
al infarction, hemodynamically stable acute non-ST
segment elevation myocardial infarction or angina pec-
toris, with clinical symptoms and signs and a positive
result in a sports plate test, and at least one blood ves-
sel or at least one part of a vessel narrowing over 60%
found with coronary arteriography.
Exclusion criteria
Patients were excluded from the trial if they had an in-
sufficiency of the spleen-Yang in TCM, hemodynami-
cally unstable angina pectoris and acute myocardial in-
farction, severe arrhythmia, other inflammatory diseas-
es, severe heart diseases, severe dysfunction of liver and
kidney, severe primary diseases of lung and brain, psy-
chosis, or if they refused to sign the fact-knowing
agreement.
Treatment methods
Patients of both groups were treated with a standard
treatment for CHD, including nitrate drugs such as
isosorbide mononitrate tablets (Southern Betty Phar-
maceutical Co., Ltd., Linyi, China) 20 mg twice per
day; isosorbide dinitrate (Nanjing Baijingyu Pharma-
ceutical Co., Ltd., Nanjing, China) 5-10 mg, thrice
daily; and nitroglycerin (Guangzhou Baiyun Mountain
Ming Xing Pharmaceutical Co., Ltd., Guangzhou, Chi-
na) according to the individual's condition; aspirin
(Bayer Pharmaceutical Co., Ltd., Leverkusen, Germa-
ny) 100-300 mg, once per day; statins for regulating
lipids such as atorvastatin calcium tablets (Pfizer, New
York, NY, USA) 10-20 mg, once per day; and fluvas-
tatin sodium capsules (Beijing Novartis Pharma Com-
pany Limited, Switzerland) 40 mg, once per night; an-
giotensin-converting enzyme inhibitor [Benazepril tab-
lets (Beijing Novartis Pharma Co., Ltd., Beijing, Chi-
na)] 10 mg, once per day; or peduopril tablets (Les
Laboratoires Servier Industrie, Tianjin, China)
4 mg, once daily. For patients with no contraindica-
tions, β-receptor blockers [Metoprolol tablets (Astra-
Zeneca Pharmaceutical Co., Ltd., Wuxi, China)]
6.25-100 mg, twice per day; bisoprolol tablets (Merck
Co., Ltd., Darmstadt, Germany) 2.5-5.0 mg, once per
day were used for long-term treatment over the whole
course of the study.
There was no statistical difference between the type of
drugs, dose, and administration time-course for the
standard treatment in the two groups.
For patients in the treatment group, Liandouqingmai
recipe composed of Lianqiao (Fructus Forsythiae) 15 g,
Huanglian (Rhizoma Coptidis) 3 g, Yeliaodou (Glycine
soja Sieb) 15 g, Chishao (Radix Paeoniae) 10 g,
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Laifuzi (Semen Raphani) 10 g, and so on, was added
to the standard treatment. The recipe was prepared
by the Pharmaceutics Department of our hospital
and the herbs were purchased from Tianjiang Phar-
maceutical Factory. The decoction (250 mL) was ad-
ministered orally twice a day, for 2 weeks as one
course of treatment.
Collection and preservation of samples
Either 4 or 6 mL of venous blood was taken from pa-
tients the morning after fasting within 24 h after hospi-
talization and added to a dry tube and kept for 1 h at
room temperature, then centrifuged for 10 min at
3000 r/min. Part of the supernatant was used for IL-6
and IL-10 determination immediately. Another part of
the supernatant was used for hs-CRP determination.
Finally, 2 mL of venous blood was slowly poured into a
tube with 30 μL 10% ethylene diamine tetraacetic acid
(EDTA) and mixed for PBL determination.
Observation indexes and determination methods
IL-6 and IL-10 were determined by IMMULITE 1000
full-automatic chemiluminescence immunoanalyzer
(Siemens Co., Munich, Germany). hs-CRP was deter-
mined by AU5800 fully automatic biochemical analyz-
er (Beckman Coulter, Brea, CA, USA). Five classifica-
tion XE2100 automatic blood analyzers (SYSMEX, Ko-
be, Japan) were used to determine PBL counts.
Before and 2 weeks after treatment, the physical limita-
tion (PL), angina stability (AS), angina frequency (AF),
treatment satisfaction (TS), and disease perception
(DP) were scored by the same deputy chief physician
using paper SAQ scales.
Statistical analysis
The data were analyzed with SPSS 17.0 software (SPSS
Company, Chicago, IL, USA). Measurement data were
expressed as the mean ± standard deviation ( xˉ ± s).
Two-sided Student t-test of two independent samples
was used for between-group comparisons of therapeu-
tic effects, and paired samples were used for in-group
comparisons before and after treatment. Correlation
was analyzed by Pearson correlation. A value of P<0.05
indicated statistical significance.
RESULTS
Effect of Liandouqingmai recipe on SAQ scores
Before treatment, there was no significant difference in
PL, AS, AF, TS, and DP scores between the two groups
(Table 1, P>0.05). After treatment, the AS and DP
scores in the control group were significantly increased
(P<0.01) compared with the treatment group; howev-
er, in the treatment group, the PL, AS, AF, TS, and DP
scores were significantly increased (P<0.01).
Effect of Liandouqingmai recipe on IL-6, IL-10,
hs-CRP, and PBL Before treatment, the IL-6 and IL-10
levels of CHD patients were significantly higher than
those of the normal group (Table 2, P>0.05). There
was no significant difference in the IL-6, hs-CRP, and
PBL levels between the treatment group and control
group.
After treatment, the mean levels of IL-6, IL-10,
hs-CRP, and PBL in the treatment and control groups
were all decreased although the differences were statisti-
cally significant (P<0.05). IL-6, hs-CRP, and PBL lev-
Table 1 Effects of Liandouqingmai recipe on SAQ scores ( xˉ ±s)
Group
Control
Treatment
Before
After
Before
After
PL
60±11
59±11
63±13
78±10a,b
AS
62±22
80±13a
63±24
89±10a,b
AF
69±22
71±13
65±22
85±12a,b
TS
71±13
67±10
67±14
82±12a,b
DP
58±18
71±17a
61±18
81±17a,b
Notes: treatment group was given standard treatment plus Liandouqingmai recipe twice a day, for 2 weeks; control group was given stan-
dard treatment only for 2 weeks. SAQ: seattle angina questionnaire; PL: physical limitation; AS: angina stability; AF: angina frequency; TS:
treatment satisfaction; DP: disease perception. Compared with data before treatment, aP<0.01; compared with control group, bP<0.01.
Group
Normal
Control
Treatment
Before
After
Before
After
T-STD
(mv)
-
0.72±0.18
0.29±0.12a
0.73±0.21
0.24±0.10a,b
IL-6
(pg/mL)
1.10±0.08
9.22±2.05
5.13±1.85a
9.11±1.36
4.48±1.22a,b
IL-10
(pg/mL)
1.09±0.06
1.95±0.32
1.65±0.18
1.93±0.19
1.82±0.19
hs-CRP
(mg/L)
1.22±0.34
9.22±4.63
8.92±2.87a
7.38±3.94
3.47±1.03a,b
PBL
(×109/L)
4.17±0.76
7.20±0.50
6.61±0.47a
6.51±0.30
5.55±0.43a,b
Table 2 Effects of Liandouqingmai recipe on T-STD, IL-6, IL-10, hs-CRP, and PBL levels ( xˉ ±s)
Notes: treatment group was given standard treatment plus Liandouqingmai recipe twice a day, for 2 weeks; control group was given stan-
dard treatment only for 2 weeks. T-STD: total values of ST segment down on electrocardiogram; IL-6: interleukin-6; IL-10: interleu-
kin-10; hs-CRP: high-sensitivity C-reactive protein; PBL: peripheral blood leucocytes. Compared with data before treatment, aP<0.05;
compared with the control group, bP<0.05.
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els in the treatment group were significantly lower than
in the control group (P<0.05). The mean levels of
IL-10 in the treatment and control groups were de-
creased and between-group and in-group comparisons
showed no statistical significance before and after treat-
ment (P>0.05).
Correlation between SAQ scores and inflammatory
indexes
SAQ scores were negatively correlated with IL-6 and
IL-10 levels, and there was a significant negative corre-
lation between IL-10 and AS (r=﹣0.15, P<0.05) (Ta-
ble 3).
DISCUSSION
Studies have shown that almost one in three patients
with stable angina attending primary care practices had
angina at least once a week, which was associated with
worse quality of life than those with minimal angina
(less than once a week over the preceding 4 weeks).5
herefore, the aim of treatment of CHD is not only to
ease the clinical symptoms but also to improve the pa-
tients' quality of life. This is an important index to eval-
uate the effects of drug treatment.
At present, SAQ is widely used to clinically evaluate
the quality of life of CHD patients. It contains 11
items in five categories: limited degree of body activi-
ties (question 1), stable state of angina pectoris (ques-
tion 2), heart attacks (questions 3-4), treatment satis-
faction (questions 5-8), and disease understanding
(questions 9-11). The total score is 100 points. The
higher the score, the better the quality of life and body
function of the patients. This system has good reliabili-
ty, validity and reaction,6 and can be used to evaluate
the quality of life of CHD patients.
Inflammatory reactions are an important mechanism
affecting the stable state of angina pectoris and quality
of life of CHD patients. hs-CRP is an important index
to calculate cardiovascular events. The risk of cardiac
infarction increases with an increase of hs-CRP. An in-
crease in PBLs is an independent risk factor for CHD
patients.
IL-6 is a strong inflammatory factor that induces in-
flammatory responses, which generates increased vascu-
lar endothelial active oxygen clusters; thus, oxygen free
radicals evoke oxidative stress and induce dysfunction
of vascular endothelium, which accelerate AS.10 Plasma
IL-6 concentrations in patients with unstable angina
pectoris are significantly higher than in patients with
stable angina pectoris or normal healthy subjects.11
IL-10 is the main anti-inflammatory cytokine, and di-
rectly inhibits the expression of adhesion molecules,
prevents ischemia/reperfusion lesions of the myocardi-
um, and protects myocardium. IL-10 also reduces me-
talloprotease activity in coronary artery plaques.12
IL-10 was negatively associated with AS (r=﹣0.15, P<
0.05). This indicated that inflammatory reactions are
closely related to CHD patient myocardial ischemia
and quality of life, especially in AS.
Inflammatory responses are important in the occur-
rence and development of AS and CHD. Therefore, in-
hibiting the inflammatory response is very important
for the treatment of CHD.
Antibiosis and anti-inflammation effects of Huanglian
(Rhizoma Coptidis) and Lianqiao (Fructus Forsythiaein),
are well known clinically. It was shown that an extract
of Huanglian (Rhizoma Coptidis) reduced breaking
times of aortic atherosclerotic plaques in ApoE-gene
knockout mice, helping stabilize vulnerable atheroscle-
rotic plaques.13 On the basis of standard treatment, Li-
andouqingmai recipe might decrease IL-6, IL-10,
hs-CRP, and PBL concentrations, inhibit the injuring
actions of IL-6 on vascular endothelium, improve myo-
cardial ischemia, and thus improve the quality of life of
CHD patients.
The standard treatment for CHD improved the AS
and DP scores, stabilized the state of angina pectoris,
and helped the disease understanding of CHD pa-
tients. When the Liandouqingmai recipe was added to
the standard treatment, the levels of PL, AS, AF, TS,
and DP in the treatment group were all increased, indi-
cating it relieved the limited degree of body activity,
improved the stable state of angina pectoris, reduced
heart attacks, and enhanced the treatment satisfaction
and disease understanding of CHD patients. SAQ
scores for PL, AS, AF, TS, and DP in the treatment
group were significantly higher than those in the con-
trol group.
In conclusion, the Liandouqingmai recipe, on the basis
of standard treatment, improved the quality of life of
CHD patients.
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